1. Introduction {#sec1-ijms-20-04482}
===============

Lung cancer (non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)) is the leading cause of cancer-related deaths among men and women in developed countries, including Japan. In 2018, approximately 2,300,000 people were diagnosed with lung cancer, and 1,800,000 patients died from this disease \[[@B1-ijms-20-04482]\]. NSCLC (accounting for approximately 80% of lung cancer cases) is divided mainly into three subtypes: lung adenocarcinoma (LUAD), squamous cell carcinoma (LUSQ), and large cell carcinoma \[[@B2-ijms-20-04482]\]. Approximately 40% of patients with lung cancer have LUAD, and this type of lung cancer is often observed in patients (especially young women) who have never smoked, in contrast to other types of lung cancers \[[@B3-ijms-20-04482]\].

LUAD has been extensively studied using molecular biology analyses, and various treatment options have been developed as a result. Based on the mutation statuses of cancer cells, several molecular targeted drugs have been available (e.g., epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors), and these treatments have dramatically improved patient outcomes \[[@B4-ijms-20-04482],[@B5-ijms-20-04482]\]. However, these treatment effects are limited because acquired resistance and cancer recurrence occur in almost all patients \[[@B6-ijms-20-04482]\].

Human genome research has revealed that the human genome encodes a large number of protein-noncoding RNA molecules, which are transcribed and have various important functions \[[@B7-ijms-20-04482]\]. microRNAs (miRNAs) are small, noncoding RNAs that act as fine-tuners of RNA expression in cells \[[@B8-ijms-20-04482]\]. Notably, bioinformatics predictions have shown that a single miRNA can control a vast number of RNA transcripts in cells, and more than half of RNAs in the human genome are controlled by miRNAs \[[@B9-ijms-20-04482]\]. The search for molecular networks controlled by miRNAs has provided us with novel knowledge of RNA networks in normal and diseased cells.

Aberrantly expressed miRNAs disrupt RNA networks and enhance cancer cell aggressive phenotypes (e.g., development, metastasis, and drug resistance) \[[@B10-ijms-20-04482]\]. Identification of tumor-suppressive or oncogenic miRNAs and their target cancer-related genes has contributed to understanding of the molecular pathogenesis of human cancers \[[@B11-ijms-20-04482]\]. Based on miRNA expression signatures, we have sequentially identified antitumor miRNAs and their target oncogenes in several cancers \[[@B12-ijms-20-04482],[@B13-ijms-20-04482],[@B14-ijms-20-04482],[@B15-ijms-20-04482]\].

In the conventional miRNA biogenesis process, the guide strand of miRNA derived from the miRNA duplex functions to control the target molecules \[[@B16-ijms-20-04482]\], whereas the passenger strand of miRNA is not incorporated into the RNA-induced silencing complex (RISC), and it is disassembled and has no function \[[@B17-ijms-20-04482]\]. However, in lung cancer, including SCLC, LUAD, and LUSQ, our recent studies showed that both strands of the miRNA duplex (e.g., *miR-144-5p/-3p* in LUSQ, *miR-145-5p*/*-3p* in LUSQ and LUAD, and *miR-150-5p*/*-3p* in LUAD) are significantly downregulated in lung cancer tissues, and these miRNAs act as tumor-suppressive miRNAs by targeting several oncogenes \[[@B18-ijms-20-04482],[@B19-ijms-20-04482],[@B20-ijms-20-04482],[@B21-ijms-20-04482]\]. Moreover, the expression levels of miRNAs and their target genes are closely associated with lung cancer pathogenesis \[[@B22-ijms-20-04482]\].

In this study, we focused on both strands of the *miR-143* duplex (*miR-143-5p*: the passenger strand, and *miR-143-3p*: the guide strand) in LUAD cells. Previous studies have shown that *miR-143-3p* functions as a tumor-suppressive miRNA in many types of cancers, and the oncogenes regulated by this miRNA duplex were identified \[[@B23-ijms-20-04482],[@B24-ijms-20-04482]\]. On the other hand, functional analysis of *miR-143-5p* in cancer cells has not previously been reported. Here, we showed that ectopic expression of *miR-143-5p* attenuated malignant phenotypes in LUAD cells. Furthermore, 11 genes (*MCM4*, *RAD51*, *FAM111B*, *CLGN*, *KRT80*, *GPC1*, *MTL5*, *NETO2*, *FANCA*, *MTFR1*, and *TTLL12*) were found to be closely associated with the molecular pathogenesis of LUAD. Identification of tumor-suppressive miRNAs and their oncogenes may be an effective strategy for elucidation of the molecular pathogenesis of this disease.

2. Results {#sec2-ijms-20-04482}
==========

2.1. Downregulation of the miR-143 Duplex (miR-143-5p and miR-143-3p) in LUAD Clinical Specimens and Cell Lines {#sec2dot1-ijms-20-04482}
---------------------------------------------------------------------------------------------------------------

Expression levels of *miR-143-5p* and *miR-143-3p* were markedly reduced in cancer tissues compared with those in normal tissues (*p* \< 0.0001 and *p* \< 0.0001, respectively; [Figure 1](#ijms-20-04482-f001){ref-type="fig"}A,B). The clinical features of LUAD specimens are listed in [Table 1](#ijms-20-04482-t001){ref-type="table"} and [Table S1](#app1-ijms-20-04482){ref-type="app"}. In two LUAD cell lines (A549 and H1299), the expression levels of these miRNAs were very low compared with those in normal tissues ([Figure 1](#ijms-20-04482-f001){ref-type="fig"}A,B). A positive correlation was detected between *miR-143-5p* and *miR-143-3p* expression levels by Spearman's rank analysis (*r* = 0.9215, *p* \< 0.0001; [Figure 1](#ijms-20-04482-f001){ref-type="fig"}C).

Cohort analysis using data from The Cancer Genome Atlas (TCGA) database showed that there was no significant relationship between expression of *miR-143-5p* or *miR-143-3p* and prognosis of patients with LUAD ([Figure S1](#app1-ijms-20-04482){ref-type="app"}).

2.2. Ectopic Expression of miR-143-5p and miR-143-3p Blocked LUAD Aggressiveness {#sec2dot2-ijms-20-04482}
--------------------------------------------------------------------------------

To investigate the functions of *miR-143-5p* and *miR-143-3p* in LUAD cells, we designed ectopic expression assays to assess cell proliferation, migration, and invasion after transfection of these miRNAs into A549 and H1299 cells. Gain-of-function assays showed that overexpression of *miR-143-5p* attenuated cell proliferation in A549 and H1299 cells ([Figure 2](#ijms-20-04482-f002){ref-type="fig"}A). However, *miR-143-3p* expression did not affect cell proliferation in A549 cells ([Figure 2](#ijms-20-04482-f002){ref-type="fig"}A). We counted LUAD cells for the antiproliferative effects of ectopic expression of *miR-143-5p* and *miR-143-3p*, and obtained similar results with the XTT assay ([Figure S2](#app1-ijms-20-04482){ref-type="app"}). Cell cycle distributions were analyzed by flow cytometry following transfection of LUAD cells with *miR-143-5p* and *miR-143-3p* (72 h after transfection). Cell cycle phase distributions (G~0~/G~1~, S, and G~2~/M) are shown in the bar chart. G~2~/M phase arrest was detected by *miR-143-5p* transfection into LUAD cells. In contrast to *miR-143-5p* transfection, G~0~/G~1~ phase arrest was detected by *miR-143-3p* transfection ([Figure 2](#ijms-20-04482-f002){ref-type="fig"}B,C).

Moreover, as shown in [Figure 3](#ijms-20-04482-f003){ref-type="fig"}A,B, the migration and invasion of A549 and H1299 cells were significantly suppressed by *miR-143-5p* or *miR-143-3p* transfection. The photomicrographs are presented in [Figure S3](#app1-ijms-20-04482){ref-type="app"}.

Due to the cell migration and invasive abilities being remarkably suppressed by *miR-143-5p* and *miR-143-3p* expression in LUAD cells, we investigated the regulation of epithelial--mesenchymal transition (EMT)-related genes (e.g., *E*-cadherin, Vimentin, *N*-cadherin, SNAIL, and SLUG) by these miRNAs. Interestingly, the expression of Vimentin, SNAIL, and SLUG was reduced by *miR-143-5p* in LUAD cells ([Figure S4](#app1-ijms-20-04482){ref-type="app"}). The elucidation of the molecular mechanism of suppression of these EMT-related genes by *miR-143-5p* is an issue for the future.

2.3. Incorporation of miR-143-5p into the RISC in LUAD Cells {#sec2dot3-ijms-20-04482}
------------------------------------------------------------

To verify that *miR-143-5p* had actual functions in LUAD cells, we performed immunoprecipitation assays using anti-Ago2 antibodies. Ago2 is an essential component of the RISC. After transfection of *miR-143-5p* into A549 cells, the amount of *miR-143-5p* was dramatically increased compared with that in untransfected cells ([Figure S5](#app1-ijms-20-04482){ref-type="app"}). These data suggested that transfected *miR-143-5p* was incorporated into the RISC in LUAD cells.

2.4. Screening of miR-143-5p-Controlled Oncogenes in LUAD Cells {#sec2dot4-ijms-20-04482}
---------------------------------------------------------------

To identify genes controlled by *miR-143-5p* in LUAD cells, we used three independent datasets: gene expression data from *miR-143-5p*-transfected A549 cells, gene expression data from lung cancer clinical specimens, and data from the TargetScanHuman database, showing annotated putative targets with *miR-143-5p* binding sites. Our strategy searching for *miR-143-5p* targets is shown in [Figure S6](#app1-ijms-20-04482){ref-type="app"}. In this study, 22 genes were identified as putative *miR-143-5p*-controlled oncogenes in LUAD cells ([Table 2](#ijms-20-04482-t002){ref-type="table"}). We also identified *miR-143-3p*-controlled oncogenic targets using a similar strategy ([Figure S6, Table S2](#app1-ijms-20-04482){ref-type="app"}).

2.5. Clinical Significance of miR-143-5p Targets in LUAD Pathogenesis {#sec2dot5-ijms-20-04482}
---------------------------------------------------------------------

Next, we investigated the clinical significance of the 22 target genes in the pathogenesis of LUAD by using TCGA database. Among the 22 targets, high expression of 11 genes (*MCM4*, *RAD51*, *FAM111B, CLGN*, *KRT80*, *GPC1*, *MTL5*, *NETO2*, *FANCA*, *MTFR1*, and *TTLL12*) was closely associated with poor prognosis (overall survival rate: *p* \< 0.05) in patients with LUAD ([Table 2](#ijms-20-04482-t002){ref-type="table"} and [Figure 4](#ijms-20-04482-f004){ref-type="fig"}). Interestingly, multivariate analysis revealed that expression levels of six genes (*MCM4*, *FAM111B*, *CLGN*, *MTL5*, *FANCA*, and *MTFR1*) were independent predictive factors for overall survival rate in these patients ([Figure 5](#ijms-20-04482-f005){ref-type="fig"}).

We then examined the regulation of these 11 genes by *miR-143-5p* in LUAD cells. We confirmed that eight genes (*MCM4*, *RAD51*, *FAM111B*, *GPC1*, *NETO2*, *FANCA*, *MTFR1*, and *TTLL12*) were downregulated in *miR-143-5p* transfected in A549 and H1299 cells ([Figure 6](#ijms-20-04482-f006){ref-type="fig"}).

2.6. Direct Regulation of MCM4 Expression by miR-143-5p in LUAD Cells {#sec2dot6-ijms-20-04482}
---------------------------------------------------------------------

From our present data ([Table 2](#ijms-20-04482-t002){ref-type="table"}, [Figure 4](#ijms-20-04482-f004){ref-type="fig"}, [Figure 5](#ijms-20-04482-f005){ref-type="fig"} and [Figure 6](#ijms-20-04482-f006){ref-type="fig"}), it has become clear that the four genes (*MCM4*, *FAM111B*, *FANCA,* and *MTFR1*) are under the control of antitumor *miR-143-5p* and are involved in the malignant transformation of LUAD.

We focused on further evaluation of *MCM4* in LUAD cells. Expression levels of *MCM4* mRNA and MCM4 protein were significantly reduced by *miR-143-5p* transfection in A549 and H1299 cells ([Figure 7](#ijms-20-04482-f007){ref-type="fig"}A,B).

Next, we performed dual-luciferase reporter assays to determine whether *MCM4* was directly regulated by *miR-143-5p*. We used vectors encoding the partial wild-type sequences of the 3′- untranslated region (UTR) of *MCM4* including the predicted *miR-143-5p* target sites (binding site 1: positions 448--454, binding site 2: positions 968--974 in the *MCM4* 3′-UTR) or deletion vectors lacking these sites ([Figure 7](#ijms-20-04482-f007){ref-type="fig"}C). We found that the luciferase activity was significantly decreased by cotransfection with *miR-143-5p* and the vector carrying the wild-type 3′-UTR of *MCM4*, whereas transfection with the deletion vector blocked the decrease in luminescence in A549 cells ([Figure 7](#ijms-20-04482-f007){ref-type="fig"}D). These data demonstrated that *miR-143-5p* directly bound to two sites in the 3′-UTR of *MCM4*.

2.7. Effects of MCM4 Knockdown on LUAD Cells Malignant Phenotypes {#sec2dot7-ijms-20-04482}
-----------------------------------------------------------------

To investigate the oncogenic functions of *MCM4* in LUAD cells, knockdown assays were conducted using small interfering RNAs (siRNAs). Both mRNA and protein expression levels were successfully suppressed by si*MCM4* transfection in A549 and H1299 cells ([Figure 8](#ijms-20-04482-f008){ref-type="fig"}A,B).

In functional assays, cell proliferation was significantly suppressed by si*MCM4* transfection into A549 and H1299 cells ([Figure 8](#ijms-20-04482-f008){ref-type="fig"}C). Cell migration and invasive abilities were significantly blocked by knockdown of *MCM4* (si*MCM4*-1 and si*MCM4*-2) in LUAD cells ([Figure 8](#ijms-20-04482-f008){ref-type="fig"}D,E). The photomicrographs were presented in [Figure S7](#app1-ijms-20-04482){ref-type="app"}. Cell cycle assays showed that significant G~0~/G~1~ phase arrest was observed in LUAD cells ([Figure S8](#app1-ijms-20-04482){ref-type="app"}). In functional assays, cell proliferation was significantly suppressed by si*MCM4* transfection into A549 and H1299 cells ([Figure 8](#ijms-20-04482-f008){ref-type="fig"}C). Moreover, cell migration and cell invasion were significantly suppressed by si*MCM4* transfection into A549 and H1299 cells ([Figure 8](#ijms-20-04482-f008){ref-type="fig"}D,E). Notably, cell cycle assays by *MCM4* knockdown showed that significant G~0~/G~1~ phase arrest was observed in LUAD cells ([Figure S8](#app1-ijms-20-04482){ref-type="app"}). Ectopic expression of *miR-143-5p* induced the S phase arrest or delayed the S phase progression ([Figure 2](#ijms-20-04482-f002){ref-type="fig"}). *MCM4* is one of the pivotal genes directly controlled by *miR-143-5p* in LUAD cells. This suggests that *miR-143-5p* also regulates other cell-cycle-related genes involved in S phase progression.

2.8. Aberrant Expression of MCM4 in LUAD Clinical Specimens by Immunohistochemistry {#sec2dot8-ijms-20-04482}
-----------------------------------------------------------------------------------

MCM4 expression at the protein levels were evaluated by using tissue microarray of 20 LUAD cases and 14 noncancerous cases ([Table S3](#app1-ijms-20-04482){ref-type="app"}). Compared with normal lung tissues, MCM4 protein was strongly expressed in LUAD tissues ([Figure 9](#ijms-20-04482-f009){ref-type="fig"}A--D).

We also investigated the expression of MCM4 using *miR-143-5p*-measured clinical specimens. Overexpression of MCM4 was detected in LUAD clinical specimens ([Table S1 and Figure S9](#app1-ijms-20-04482){ref-type="app"}).

3. Discussion {#sec3-ijms-20-04482}
=============

Several miRNAs exist in close proximity on the human genome (defined as miRNA clusters). The expression levels of miRNAs within miRNA clusters are controlled by the same molecular mechanisms \[[@B25-ijms-20-04482]\]. In the human chromosome 5q32 region, pre-*miR-143* and pre-*miR-145* form the miRNA cluster, and their promoter regions contain p53 binding sites, resulting in p53-dependent expression \[[@B26-ijms-20-04482]\]. Many studies have shown that *miR-143*/*miR-145* cluster miRNAs are frequently downregulated in human cancers where *miR-143-3p* and *miR-145-5p* (the guide strand) act as pivotal tumor suppressors \[[@B27-ijms-20-04482],[@B28-ijms-20-04482]\]. Extensive searches have been carried out to identify the oncogenic targets and molecular networks controlled by *miR-143-3p* and *miR-145-5p* in several cancers \[[@B27-ijms-20-04482],[@B28-ijms-20-04482],[@B29-ijms-20-04482]\]. In contrast, few studies have evaluated functional roles and targets of *miR-143-5p* and *miR-145-3p* (the passenger strand) in cancer cells.

Recently, we found that the expression levels of both strands of pre-*miR-145* (*miR-145-5p* and *miR-145-3p*) were reduced in LUAD clinical specimens and that cancer cell malignant phenotypes were attenuated by ectopic expression of these miRNAs \[[@B20-ijms-20-04482]\]. Furthermore, target searches for *miR-145-5p*/*miR-145-3p* showed that aberrant expression of *LMNB2* acted as an oncogene in LUAD cells \[[@B20-ijms-20-04482]\]. Our previous studies revealed that tumor-suppressive *miR-145-3p* was closely involved in human cancer pathogenesis by targeting oncogenes, for example, *MTDH* in LUSQ; *MELK*, *NCAPG*, *BUB1*, and *CDK1* in prostate cancer; *MYO1B* in head and neck cancer; and *MYO1B* and *DHRS2* in esophageal cancer \[[@B19-ijms-20-04482],[@B30-ijms-20-04482],[@B31-ijms-20-04482],[@B32-ijms-20-04482]\]. These data suggest that some passenger strands of miRNAs are actually functional in human cancers.

In this study, we focused on *miR-143-5p* and demonstrated the tumor-suppressive functions of this miRNA, similar to those of *miR-143-3p*, in LUAD cells. Previous studies have shown that *miR-143-5p* is downregulated in gastric cancer and gallbladder cancer tissues and that forced *miR-143-5p* expression suppresses cancer cell malignancy through targeting *COX-2* and *HIF1-alpha*, respectively \[[@B33-ijms-20-04482],[@B34-ijms-20-04482]\]. Interestingly, recent reports have indicated that some long noncoding RNAs (e.g., *lncRNA-TCONS_00026907*, *ZEB2-AS1*, and *LINC01207*) suppress *miR-143-5p* expression to enhance cancer cell aggressiveness \[[@B35-ijms-20-04482],[@B36-ijms-20-04482],[@B37-ijms-20-04482]\]. These findings were consistent with our current results in LUAD cells.

Next, we identified cancer-promoting genes and oncogenic molecular networks regulated by tumor-suppressive *miR-143-5p* in LUAD cells. In this screening, we successfully identified 22 putative target oncogenes regulated by *miR-143-5p* in LUAD cells. Among these targets, high expression of 11 genes (*MCM4*, *RAD51*, *FAM111B*, *CLGN*, *KRT80*, G*PC1*, *MTL5*, *NETO2*, *FANCA*, *MTFR1*, and *TTLL12*) was significantly associated with poor prognosis in patients with LUAD. Moreover, multivariate analysis revealed the expression levels of six genes (*MCM4*, *FAM111B*, *CLGN*, *MTL5*, *FANCA*, and *MTFR1*) were independent predictive factors for overall survival in patients. Recently, overexpression of *MTL5* was reported in NSCLC, and its expression was shown to predict prognosis \[[@B38-ijms-20-04482]\]. Another study showed that knockdown of *FAM111B* induced G~2~/M phase arrest and apoptosis in LUAD cells \[[@B39-ijms-20-04482]\]. These data suggested that *miR-143-5p*-controlled genes were closely involved in LUAD oncogenesis and molecular pathogenesis.

In this study, we further analyzed the roles of *MCM4* in LUAD cells. Our data revealed that aberrant expression of *MCM4* enhanced LUAD cell proliferation and that *MCM4* expression was an independent prognostic biomarker in patients with LUAD. Our data were consistent with a previous report \[[@B20-ijms-20-04482]\], strongly suggesting that aberrantly expressed *MCM4* was an oncogene in LUAD.

Minichromosome maintenance (MCM) proteins (MCM2--MCM7) form a hexamer complex that functions as a DNA helicase in DNA replication \[[@B40-ijms-20-04482]\]. Moreover, the MCM2-7 hexamer helicase is activated by forming a complex with CDC45 and GINS proteins, termed the CMG (CDC45/MCMs/GINS) complex \[[@B40-ijms-20-04482]\]. Notably, TCGA database analyses showed that high expression of *CDC45*, *GINS1*, and *GINS3* was associated with a poor prognosis compared to low expression of these genes in patients with LUAD. Moreover, aberrant expression of MCM proteins has been shown to contribute to cancer progression, and these proteins could be effective diagnostic markers in various cancers \[[@B41-ijms-20-04482]\]. In lung cancer, high expression levels of *MCM2*, *MCM5*, *MCM6*, and *MCM7* could be useful prognostic markers \[[@B41-ijms-20-04482],[@B42-ijms-20-04482],[@B43-ijms-20-04482]\].

This is the first report demonstrating that tumor-suppressive *miR-143-5p* directly regulates *MCM4* in LUAD cells. However, our understanding of the molecular mechanisms controlling the expression of MCM proteins is insufficient. Recent studies have reported that tumor-suppressive miRNAs negatively regulate the expression of MCM family genes (e.g., *MCM2* is targeted by *miR-31* and *MCM5* is targeted by *miR-885-5p* and *miR-362-3p*) \[[@B44-ijms-20-04482],[@B45-ijms-20-04482],[@B46-ijms-20-04482]\]. Interestingly, reduced expression of MCM2-7 in DNA replication stress is associated with p53-dependent miRNAs, including the miR-34-family \[[@B47-ijms-20-04482]\]. Future studies are needed to determine the involvement of noncoding RNAs, including miRNAs, in the regulation of MCM/CMG expression.

Our results showed that all members of the *miR-143*/*miR-145* cluster (*miR-143-5p*, *miR-143-3p*, *miR-145-5p*, and *miR-145-3p*) acted as tumor-suppressive miRNAs in LUAD. The involvement of passenger strands of miRNAs in LUAD oncogenesis is a novel concept in cancer research. The tumor-suppressive functions of miRNAs depend on controlling a vast number of oncogenic genes in the cancer cell. Our present study suggests that the *miR-143-5p* regulates cell-cycle-related genes and EMT-related genes in LUAD cells. The *miR-143-5p* may control many genes contributing to LUAD malignancy. Identification of oncogenes and oncogenic networks controlled by the *miR-143*/*miR-145* cluster could help to establish novel prognostic and therapeutic targets in LUAD.

4. Materials and Methods {#sec4-ijms-20-04482}
========================

4.1. Clinical Human LUAD Specimens and LUAD Cell Lines {#sec4dot1-ijms-20-04482}
------------------------------------------------------

Forty-three clinical specimens (19 LUAD and 24 normal lung tissues) were used in this study. The clinical characteristics of these specimens are summarized in [Table 1](#ijms-20-04482-t001){ref-type="table"} and [Table S1](#app1-ijms-20-04482){ref-type="app"}. Classification of sample stages was carried out according to the Association for the Study of Lung Cancer TNM classification (7th edition).

All specimens were obtained from lung cancer surgeries performed at Kagoshima University Hospital (2010--2013). Written informed consent was obtained from all patients before the use of their specimens. This study was approved by the Bioethics Committee of Kagoshima University (approval number: 26-164, 10th February 2015).

Two LUAD cell lines, A549 and H1299 (American Type Culture Collection, Manassas, VA, UAS), were used in this study.

4.2. RNA Preparation and Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) {#sec4dot2-ijms-20-04482}
---------------------------------------------------------------------------------------------------------

RNA extraction from clinical specimens and cell lines was performed as previously described \[[@B21-ijms-20-04482],[@B48-ijms-20-04482]\]. Expression levels of miRNAs were evaluated using qRT-PCR as described previously \[[@B21-ijms-20-04482],[@B48-ijms-20-04482]\]. TaqMan probes and primers used in this study are listed in [Table S4](#app1-ijms-20-04482){ref-type="app"}.

4.3. Transfection of miRNAs, siRNAs, and Plasmid Vectors into LUAD Cells {#sec4dot3-ijms-20-04482}
------------------------------------------------------------------------

The procedures for transfection of miRNAs, siRNAs, and plasmid vectors into LUAD cells were described previously \[[@B21-ijms-20-04482],[@B48-ijms-20-04482]\]. The reagents used in this study are listed in [Table S4](#app1-ijms-20-04482){ref-type="app"}.

4.4. Functional Assays for LUAD Cells (i.e., Cell Proliferation, Migration, Invasion, and Cell Cycle Assays) {#sec4dot4-ijms-20-04482}
------------------------------------------------------------------------------------------------------------

The procedures for functional assays in cancer cells (proliferation, migration, invasion, and cell cycle assays) were described in our previous studies \[[@B21-ijms-20-04482],[@B48-ijms-20-04482]\].

4.5. Measurement of Amount of miR-143-5p Incorporated into the RISC {#sec4dot5-ijms-20-04482}
-------------------------------------------------------------------

Immunoprecipitation using anti-Ago2 antibodies was used to determine whether *miR-143-5p* was incorporated into the RISC. The procedure for immunoprecipitation was described in a previous study \[[@B31-ijms-20-04482]\]. The reagents used in this study are listed in [Table S4](#app1-ijms-20-04482){ref-type="app"}.

4.6. Identification of Oncogenes Regulated by miR-143-5p and miR-143-3p in LUAD Cells {#sec4dot6-ijms-20-04482}
-------------------------------------------------------------------------------------

The strategy for identification of miRNA targets in this study is summarized in [Figure S6](#app1-ijms-20-04482){ref-type="app"}. Three expression profiles (i.e., *miR-143-5p*-transfected A549 cells (GEO accession number: GSE123318), *miR-143-3p*-transfected A549 cells (accession number: GSE123318), and LUAD clinical specimens (accession number: GSE19188)), were used in this screening. TargetScanHuman database (<http://www.targetscan.org/ver_72/>) was used to predict miRNA binding sites.

4.7. Plasmid Construction and Dual-Luciferase Reporter Assay {#sec4dot7-ijms-20-04482}
------------------------------------------------------------

Plasmid vectors, including vectors containing the wild-type sequence of *miR-143-5p* binding sites in the 3′-UTR of *MCM4* or the deletion sequences of *miR-143-5p* binding sites in the 3′-UTR of *MCM4*, were prepared. The inserted sequences are shown in [Figure S10](#app1-ijms-20-04482){ref-type="app"}. The procedures for transfection and dual luciferase reporter assays were described in our previous studies \[[@B21-ijms-20-04482],[@B48-ijms-20-04482]\]. The reagents used in this study are listed in [Table S4](#app1-ijms-20-04482){ref-type="app"}.

4.8. Clinical Data Analyses of miRNAs and Target Genes in LUAD Specimens {#sec4dot8-ijms-20-04482}
------------------------------------------------------------------------

TCGA (<https://tcga-data.nci.nih.gov/tcga/>) was applied to investigate the clinical significance of miRNAs and their target genes. Gene expression and clinical data were obtained from cBioPortal (<http://www.cbioportal.org/>) and OncoLnc (<http://www.oncolnc.org/>) (data downloaded on October 11, 2018).

4.9. Western Blotting and Immunohistochemistry {#sec4dot9-ijms-20-04482}
----------------------------------------------

The procedures for Western blotting and immunohistochemistry were described in our previous studies \[[@B21-ijms-20-04482],[@B48-ijms-20-04482]\]. MCM4 expression at the protein levels were evaluated by immunohistochemical staining using tissue microarray (BC04002a; US Biomax, Inc. Derwood, MD, USA) of 20 LUAD cases and 14 noncancerous cases ([Table S3](#app1-ijms-20-04482){ref-type="app"}). The expression of MCM4 using *miR-143-5p*-measured clinical specimens was investigated ([Table S1 and Figure S9](#app1-ijms-20-04482){ref-type="app"}). The antibodies used in this study are listed in [Table S4](#app1-ijms-20-04482){ref-type="app"}.

4.10. Statistical Analysis {#sec4dot10-ijms-20-04482}
--------------------------

Mann--Whitney U tests were applied for comparisons between two groups. For multiple groups, one-way analysis of variance and Tukey tests for post hoc analysis were applied. These analyses were performed with GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) and JMP Pro 14 (SAS Institute Inc., Cary, NC, USA).

5. Conclusions {#sec5-ijms-20-04482}
==============

This is the first report revealing that *miR-143-5p* (the passenger strand of the *miR-143* duplex) had tumor-suppressive functions in LUAD cells. Several genes controlled by *miR-143-5p* were closely involved in LUAD oncogenesis and pathogenesis. Notably, the expression of *MCM4* was directly regulated by *miR-143-5p*, and its aberrant expression enhanced LUAD malignant transformation. Our studies demonstrated that all members of the *miR-143*/*miR-145* cluster acted as tumor-suppressive miRNAs and that their targets may be novel prognostic and therapeutic targets in LUAD.

Supplementary materials can be found at <https://www.mdpi.com/1422-0067/20/18/4482/s1>.
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Click here for additional data file.
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![Expression of *miR-143-5p* and *miR-143-3p* in LUAD clinical specimens and cell lines. (**A**) Downregulation of *miR-143-5p* was detected in LUAD specimens and cell lines (A549 and H1299 cells). Data were normalized according to the expression of *RNU48* (internal control). (**B**) Downregulation of *miR-143-3p* was detected in clinical specimens and cell lines. (**C**) *miR-143-5p* and *miR-143-3p* expression levels were positively correlated in clinical specimens, as demonstrated by Spearman's rank tests.](ijms-20-04482-g001){#ijms-20-04482-f001}

![Cell proliferation and cell cycle assays in LUAD cell lines with ectopic expression of *miR-143-5p* and *miR-143-3p*. (**A**) Cell proliferation was assessed using XTT assays. Data were measured 72 h after transfection with miRNAs. Cell proliferation was suppressed by *miR-143-5p* and *miR-143-3p* in H1299 cells (\* *p* \< 0.001), but it was not affected by *miR-143-3p* transfection into A549 cells. (**B**,**C**) Cell cycle assays by flow cytometry showed that G~2~/M phase arrest was induced following *miR-143-5p* transfection into A549 and H1299 cells. In contrast to *miR-143-5p* transfection, G~0~/G~1~ phase arrest was detected by *miR-143-3p* transfection.](ijms-20-04482-g002){#ijms-20-04482-f002}

![Cell migration and invasion assays in LUAD cells with ectopic expression of *miR-143-5p* and *miR-143-3p*. Cells were transfected with *miR-143-5p* and *miR-143-3p*. (**A**) Cell migration was measured (48 h after wounding the cells) by wound healing assays (\* *p* \< 0.001). (**B**) Cell invasion was determined (48 h after seeding cells into the chamber) by Matrigel invasion assays (\* *p* \< 0.001, \*\* *p* \< 0.05).](ijms-20-04482-g003){#ijms-20-04482-f003}

![Clinical significance of *miR-143-5p* target genes in TCGA database. Among putative targets of *miR-143-5p* in LUAD cells, high expression of 11 genes (*MCM4*, *RAD51, FAM111B*, *CLGN*, *KRT80*, *GPC1*, *MTL5*, *NETO2*, *FACNCA*, *MTFR1*, and *TTLL12*) was significantly associated with poor prognosis in patients with LUAD. Kaplan--Meier curves of 5-year overall survival and 5-year disease-free survival are shown.](ijms-20-04482-g004){#ijms-20-04482-f004}

![Multivariate analysis of six genes (*MCM4*, *FAM111B*, *CLGN*, *MTL5*, *FANCA*, and *MTFR1*). These genes were independent prognostic factors for overall survival.](ijms-20-04482-g005){#ijms-20-04482-f005}

###### 

Expression of *miR-143-5p* target genes was evaluated using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). (**A**) *MCM4*, (**B**) *RAD51*, (**C**) *FAM111B*, (**D**) *CLGN*, (**E**) *KRT80*, (**F**) *GPC1*, (**G**) *MTL5*, (**H**) *NETO2*, (**I**) *FANCA*, (**J**) *MTFR1*, (**K**) *TTLL12*. Expression of *GAPDH* was used as an internal control (\* *p* \< 0.001, \*\* *p* \< 0.05).

![](ijms-20-04482-g006a)

![](ijms-20-04482-g006b)

![Expression of *MCM4*/MCM4 was directly regulated by *miR-143-5p* in LUAD cells. (**A**) Expression of *MCM4* mRNA was significantly reduced by *miR-143-5p* transfection into A549 and H1299 cells (72 h after transfection). Expression of *GAPDH* was used as an internal control. (**B**) Expression of MCM4 protein was reduced by *miR-143-5p* transfection into LUAD cells (72 h after transfection). Expression of GAPDH was used as an internal control. (**C**) TargetScanHuman database analyses predicted two putative *miR-143-5p* binding sites in the 3′-UTR of *MCM4*. (**D**) Dual luciferase reporter assays showed that luminescence activities were reduced by cotransfection with wild-type (*miR-143-5p* binding site) vectors and *miR-143-5p* in LUAD cells. Normalized data were calculated as *Renilla*/firefly luciferase activity ratios (\* *p* \< 0.001).](ijms-20-04482-g007){#ijms-20-04482-f007}

![Effects of *MCM4* silencing on cell proliferation, migration, and invasion in LUAD cells. (**A**,**B**) The effects of si*MCM4* in LUAD cells. *MCM4* mRNA and protein expression levels were significantly reduced by si*MCM4* transfection into A549 and H1299 cells (72 h after transfection). Expression of *GAPDH*/GAPDH was used as an internal control. (**C**) Cell proliferation activities were blocked by si*MCM4* transfection into LUAD cells. (**D**,**E**) Cell migration and invasive abilities were blocked by si*MCM4* transfection into LUAD cells (\* *p* \< 0.001).](ijms-20-04482-g008){#ijms-20-04482-f008}

![Aberrant expression of MCM4 in LUAD clinical specimens. Patient characteristics showed in [Table S3](#app1-ijms-20-04482){ref-type="app"}. (**A**--**C**) Expression of MCM4 was investigated by immunohistochemistry staining of LUAD specimens and normal lung tissues. Overexpression of MCM4 was detected in nuclei of cancer lesions, whereas negative or low expression of MCM4 was observed in normal lung tissue (**A**; patient no.16, **B**; patient no.19, **C**; patient no.31). (**D**) Comparison of the scoring of MCM4 expression in clinical lung specimens. Expression scores of MCM4 in LUAD tissues were significantly higher than those in normal lung tissue (\* *p* = 0.0414).](ijms-20-04482-g009){#ijms-20-04482-f009}
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###### 

Characteristics of patients with LUAD and noncancerous controls.

  A. Characteristics of Patients with LUAD                   
  ------------------------------------------ --------------- ------
  **Patients with Lung Cancer**              **n**           (%)
  Total number                               19              
  Median age (range)                         73 (57--86)     
  Sex                                                        
  Male                                       10              52.6
  Female                                     9               47.4
  Pathological stage                                         
  IA                                         1               5.3
  IB                                         4               21.0
  IIA                                        9               47.4
  IIB                                        1               5.3
  IIIA                                       4               21.0
  B. Characteristics of controls                             
  Controls                                   n               (%)
  Total number                               24              
  Median age (range)                         72.5 (50--88)   
  Sex                                                        
  Male                                       21              87.5
  Female                                     3               12.5

ijms-20-04482-t002_Table 2

###### 

Candidate target genes regulated by *miR-143-5p.*

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez Gene   Gene Symbol   Gene Name                                                                     Total Sites   GSE19188\     A549\           TCGA\
                                                                                                                          FC (log~2~)   *miR-143-5p*\   OncoLnc\
                                                                                                                                        Transfectant\   5-Year OS\
                                                                                                                                        FC (log~2~)     *p*-Value
  ------------- ------------- ----------------------------------------------------------------------------- ------------- ------------- --------------- ------------
  4173          *MCM4*        minichromosome maintenance complex component 4                                4             3.1253        −1.0075         0.0025

  8091          *HMGA2*       high mobility group AT-hook 2                                                 3             2.8253        −2.5651         0.1389

  5888          *RAD51*       RAD51 recombinase                                                             3             2.0850        −1.0812         0.0478

  374393        *FAM111B*     family with sequence similarity 111, member B                                 2             2.0754        −1.8781         0.0003

  1047          *CLGN*        calmegin                                                                      1             1.8038        −1.1616         0.0362

  51155         *HN1*         hematological and neurological expressed 1                                    1             1.6878        −3.2334         0.4579

  222962        *SLC29A4*     solute carrier family 29 (equilibrative nucleoside transporter), member 4     3             1.6166        −1.0253         0.9072

  144501        *KRT80*       keratin 80                                                                    1             1.4711        −1.4127         0.0093

  2817          *GPC1*        glypican 1                                                                    1             1.4008        −1.1491         0.0322

  9633          *MTL5*        metallothionein-like 5, testis-specific (tesmin)                              1             1.4001        −1.0459         0.0001

  81831         *NETO2*       neuropilin (NRP) and tolloid (TLL)-like 2                                     1             1.3829        −2.5034         0.0344

  2175          *FANCA*       Fanconi anemia, complementation group A                                       5             1.3767        −1.1330         0.0218

  771           *CA12*        carbonic anhydrase XII                                                        2             1.2698        −1.5449         0.2834

  84524         *ZC3H8*       zinc finger CCCH-type containing 8                                            3             1.2393        −1.1569         0.9583

  6929          *TCF3*        transcription factor 3                                                        2             1.2092        −1.3071         0.1287

  9650          *MTFR1*       mitochondrial fission regulator 1                                             1             1.2079        −1.4214         0.0038

  29993         *PACSIN1*     protein kinase C and casein kinase substrate in neurons 1                     1             1.1587        −2.3003         0.3508

  23097         *CDK19*       cyclin-dependent kinase 19                                                    1             1.1498        −1.4269         0.8145

  1869          *E2F1*        E2F transcription factor 1                                                    1             1.1114        −1.1265         0.38

  10160         *FARP1*       FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived)   1             1.0674        −1.0327         0.0699

  23170         *TTLL12*      tubulin tyrosine ligase-like family, member 12                                4             1.0180        −1.1575         0.0127

  84419         *C15orf48*    chromosome 15 open reading frame 48                                           2             1.0106        −1.0710         0.134
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

Lower and upper percentiles of The Cancer Genome Atlas (TCGA) database were both 50. GSE: Gene Expression. Omnibus dataset results; FC: fold change; OS: overall survival.
